Skip to main
GENB

GENB Stock Forecast & Price Target

GENB Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Generate Biomedicines is well-positioned for success with their cutting-edge generative platform and partnerships, as well as promising data for their lead asset. The company also has a strong financial position, with a market capitalization of $4.2 billion and the potential for significant revenue from their asthma drug. If their programs continue to show positive results, the company could see significant growth potential in the future.

Bears say

Generate Biomedicines is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development, with a focus on using machine learning to generate novel protein therapeutics. However, despite some promising data, the company faces significant challenges in proving the efficacy and differentiation of its products in a competitive market with potential players with greater resources. Additionally, the company's timeline for achieving positive cash flow is relatively far out, which may concern investors.

GENB has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Generate Biomedicines Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Generate Biomedicines Inc (GENB) Forecast

Analysts have given GENB a Strong Buy based on their latest research and market trends.

According to 5 analysts, GENB has a Strong Buy consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Generate Biomedicines Inc (GENB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.